Keywords: Eltrombopag, Aplastic anemia, National Hear, Lund and Blood Institute, GlaxoSmithKline

Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

Article | 05 July 2012

Print This

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in